- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03076372
A Study Evaluating MM-310 in Patients With Solid Tumors
February 26, 2018 updated by: Merrimack Pharmaceuticals
A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells.
Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors.
In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established.
After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
34
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vasileios Askoxylakis, MD, PhD
- Phone Number: 617.441.7492
- Email: VAskoxylakis@merrimack.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Honor Health
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University California San Francisco
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Recruiting
- Mayo Clinic
-
-
New York
-
Buffalo, New York, United States, 14263
- Recruiting
- Roswell Park Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Must have one of the following cancers, for which the patient has either received or been intolerant to all therapy known to confer clinical benefit
- Urothelial carcinoma
- Gastric/gastroesophageal junction/esophageal carcinoma (G/GEJ/E)
- Squamous Cell Carcinoma of the Head and neck (SCCHN)
- Ovarian cancer
- Pancreatic ductal adenocarcinoma (PDAC)
- Prostate adenocarcinoma (PAC)
- Non-small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
- Triple negative breast cancer (TNBC)
- Endometrial carcinoma
- Soft tissue sarcoma subtypes except GIST, desmoid tumors and pleomorphic rhabdomyosarcoma
- Able to provide informed consent, or have a legal representative able and willing to do so
- ≥ 18 years of age
- Availability of a cancerous lesion amenable to biopsy and willing to undergo a pre-treatment biopsy
- ECOG Performance Status of 0 or 1
Adequate bone marrow reserve as evidenced by:
- ANC > 1,500/µl (unsupported by growth factors) and
- Platelet count > 100,000/µl
- Hemoglobin > 9 g/dL
- Patients must have adequate coagulation function as evidenced by prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) within normal institutional limits
Adequate hepatic function as evidenced by:
- Serum total bilirubin ≤ ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN.
- Alkaline phosphatase ≤ 2.5 x ULN, unless the elevated alkaline phosphatase is due to bone metastasis.
- In case alkaline phosphatase is >2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 x ULN
- Adequate renal function as evidenced by a serum/plasma creatinine < 1.5 x ULN
- Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia
- Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 6 months following the last dose of MM-310.
Exclusion Criteria:
- Prior treatment with docetaxel within 6 months of study enrollment
- Pregnant or lactating
- Treatment with systemic anticoagulation (e.g. warfarin, heparin, low molecular weight heparin, anti-Xa inhibitors, etc.) except aspirin
- Any evidence of hematemesis, melena, hematochezia, ≥ grade 2 hemoptysis, or gross hematuria
- Any history of hereditary bleeding disorders
- Presence of an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome. At the discretion of the investigator, patients with tumor fever may be enrolled
- Known CNS metastases
- Known hypersensitivity to the components of MM-310, or docetaxel
- Prior treatment with MM-310
- Received treatment, within 28 days or 5 half-lives, whichever is shorter, prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state and all prior clinically significant treatment related toxicities have resolved to Grade 1 or baseline
- Received other recent antitumor therapy including any standard chemotherapy or radiation within 14 days (or have not yet recovered from any actual toxicities of the most recent therapy) prior to the first scheduled dose of MM-310
- Received any anti-cancer drug known to have anti-VEGF/VEGFR activity within a period of 5 half-lives of this drug (e.g. 100 days for bevacizumab, 75 days for ramucirumab) prior to the first scheduled dose of MM-310
- Clinically significant cardiac disease, including: NYHA Class III or IV congestive heart failure, unstable angina, acute myocardial infarction within six months of planned first dose, arrhythmia requiring therapy (including torsades de pointes, with the exception of extrasystoles, minor conduction abnormalities, or controlled and well treated chronic atrial fibrillation)
- Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator
- Patients who received organ or allogeneic bone marrow or peripheral blood stem cell transplants
- Chronic use of corticosteroids more than 10mg daily prednisone equivalent during the past 4 weeks prior to planned start of MM-310
- Concomitant use of strong inhibitors of CYP3A
- Patients with peripheral neuropathy of grade 2 or higher
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MM-310 monotherapy
MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
|
MM-310
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose (MTD) of MM-310 monotherapy administered once every 3 weeks in patients with metastatic solid tumors.
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression Free Survival
Time Frame: 18 months
|
18 months
|
Serum levels of analytes that comprise MM-310
Time Frame: 18 months
|
18 months
|
Adverse event profile using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03
Time Frame: 18 months
|
18 months
|
Presence of human anti-human antibodies to MM-310
Time Frame: 18 months
|
18 months
|
Objective responses based on RECIST v1.1 or other relevant criteria
Time Frame: 18 months
|
18 months
|
Disease Control Rate
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Vasileios Askoxylakis, MD, PhD, Merrimack
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 22, 2017
Primary Completion (Anticipated)
June 1, 2018
Study Completion (Anticipated)
December 1, 2018
Study Registration Dates
First Submitted
March 1, 2017
First Submitted That Met QC Criteria
March 9, 2017
First Posted (Actual)
March 10, 2017
Study Record Updates
Last Update Posted (Actual)
February 27, 2018
Last Update Submitted That Met QC Criteria
February 26, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
- Gemcitabine
- Cancer
- Solid tumors
- non-small cell lung cancer
- Phase I
- ovarian cancer
- Carboplatin
- Oncology
- EphA2
- small cell lung cancer
- urothelial carcinoma
- squamous cell carcinoma of the head and neck
- triple negative breast cancer
- soft tissue sarcoma
- pancreatic ductal adenocarcinoma
- prostate adenocarcinoma
- gastric carcinoma
- endometrial carcinoma
- MM-310
- Ephrin A2
- Merrimack
Additional Relevant MeSH Terms
- Digestive System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Breast Neoplasms
- Sarcoma
- Stomach Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Adenocarcinoma
- Ovarian Neoplasms
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
- Carcinoma, Transitional Cell
Other Study ID Numbers
- MM-310-01-01-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on MM-310
-
Laboratoires URGOUnknownDiabetic Foot Ulcer(s)France
-
Resurge Therapeutics Inc.RecruitingLower Urinary Tract Symptoms | BPH (Benign Prostatic Hyperplasia)New Zealand, Australia
-
Laboratoires URGOCompleted
-
Woolcock Institute of Medical ResearchUniversity of SydneyCompleted
-
4D Molecular TherapeuticsActive, not recruiting
-
4D Molecular TherapeuticsActive, not recruitingFabry DiseaseUnited States
-
Umeå UniversityGlaukos CorporationCompletedEye Diseases | Refractive Errors | Myopia | Corneal CrosslinkingSweden
-
Penumbra Inc.Active, not recruitingCerebral Hemorrhage | Intracerebral Hemorrhage | Brain Hemorrhage | Cerebral Parenchymal HemorrhageUnited States, Germany, Canada, Austria
-
Medtronic VascularCompletedCoronary Artery DiseaseUnited States
-
Sun Pharmaceutical Industries LimitedMoebius Medical Ltd.; Nordic Bioscience Clinical Development (NBCD)CompletedOsteoarthritis of KneeUnited States, Denmark, Hong Kong